GlassScriptPhysician profile
Claire A Roarty
NPI 1366943110
$5,171.30
in general payments reported to CMS, 2019-2025
25 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,662 · 2022: $596 · 2023: $513 · 2024: $1,286 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.38 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $690.65 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $475.59 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $383.42 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $352.46 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $284.34 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $282.19 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $257.40 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $179.22 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $177.69 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.57 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $99.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $76.15 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $70.23 | 2024 | Ingrezza |
| Eisai INC. | $62.78 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $52.14 | 2021-2024 | Qelbree |
| Avanir Pharmaceuticals, INC. | $40.46 | 2021 | |
| Almatica Pharma LLC | $37.14 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $31.08 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $23.70 | 2025 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $21.55 | 2025 | Relexxii |
| Neuronetics, INC. | $19.16 | 2025 | Neurostar Tms Therapy System |
| Sage Therapeutics, LLC | $17.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.76 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Roarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.